0.08Open0.08Pre Close0 Volume4 Open Interest13.00Strike Price0.00Turnover240.52%IV187.47%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.08Extrinsic Value100Contract SizeAmericanOptions Type0.0794Delta0.0532Gamma56.88Leverage Ratio-0.0086Theta0.0002Rho4.52Eff Leverage0.0017Vega
Fulcrum Therapeutics Stock Discussion
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Fulcrum Therapeutics (NASDAQ: FULC) announced that its Phase 3 REACH trial for losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) failed to meet its primary endpoint. The trial showed no significant improvement in relative surface area (RSA) compared to placebo at week 48. Secondary endpoints also failed to ...
Fulcrum Therapeutics Enters Into a Collaboration and License Agreement With Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
No comment yet